Medicinal Cannabis Improves Quality of Life for Patients With High-Grade Gliomas
A 1:1 ratio of THC to CBD proved superior to a 4:1 ratio.
Brain Cancer News
BRAIN CANCER ADVISOR
Brain Cancer News
Carboplatin Intensification Beneficial for Group 3 Medulloblastoma
Therapy intensification with carboplatin improved five-year event-free survival in children with high-risk group 3 medulloblastoma only.
Very Elderly Can Benefit From Brain Tumor Surgery
While there is short-term excess mortality, cumulative survival is similar to the general population.
Adjuvant, Not Concurrent, Temozolomide Improved Survival in Certain Patients With Anaplastic Glioma
The benefit was restricted to patients with IDH1/2-mutant tumors.
ASCO and Friends: Cancer Patients Should Be Included in COVID-19 Vaccine Trials
A statement recommends including cancer patients and survivors in COVID-19 vaccine trials.
Adding Marizomib to Standard Care Did Not Improve Survival in Newly Diagnosed Glioblastoma
There was no improvement in progression-free or overall survival with marizomib.
Closing the Gap Between Cancer Patients and Researchers: A Patient Advocate’s Perspective on GRASP
Patient advocate Marlena Murphy provides a patient’s perspective on GRASP.
The Past, Present, and Future of GRASP: Connecting Cancer Researchers, Clinicians, and Patient Advocates
GRASP co-founder Julia Maués explains how the initiative came about and reveals plans for the future.
Underdosing in Patients With Cancer and Obesity: A Thing of the Past?
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.
Age and Race May Determine Whether Cancer Patients Access Their Electronic Health Records
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.
Early Radiotherapy Preserves Vision in Certain Children With Glioma
Early radiotherapy may preserve visual acuity for certain children with sporadic optic pathway/hypothalamic gliomas.
Global Variation Found in Histology Distribution of Brain Tumors
The proportion of childhood medulloblastomas varied widely between countries, offsetting the low proportion of low-grade astrocytomas in several countries.
Extended Induction Chemotherapy Does Not Improve Survival in High-Risk Neuroblastoma
Researchers found that the therapy did not improve EFS or OS in high-risk patients and also led to an increase in toxic side effects.
Weight Gain, Obesity Common Among Childhood Brain Cancer Survivors
Investigators sought to determine the prevalence of weight gain and becoming overweight or obese and its association with hypothalamic-pituitary dysfunction in survivors of childhood brain cancer.
Novel Therapy for Diffuse Intrinsic Pontine Glioma Fast Tracked
Oblato plans to evaluate OKN-007 for diffuse intrinsic pontine glioma in a phase 1/2 trial this year.
American Cancer Society 2021 Statistics Report Shows Continuous Decline in Cancer Mortality Rate, Illuminates Disease-Specific Trends
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
Biosimilars in Cancer Care: Insights From 2020 and Expectations for 2021
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
Subset of Glioblastoma Tumors Identified as Immunotherapy Candidate
Investigators performed immunohistochemistry on glioblastoma tumor samples in an effort to identify molecular subtypes associated with treatment sensitivities.
NCI-MATCH Trial Identifies Actionable Alterations in More Than One-Third of Patients With Cancer
Researchers have identified actionable alterations in nearly 38% of patients with cancer, and almost 18% of patients were assigned to treatments based on their molecular profiling results.
Novel Treatment Gains Accelerated Approval for Relapsed/Refractory Neuroblastoma
Approval was based on results from two phase 2 single-arm, open-label trials that demonstrated overall response rate and duration of response.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...